Introduction: The motor features of corticobasal syndrome (CBS) are well recognized but the fact that many, if not all, affected patients develop cognitive impairment is still underrecognized. The dementia of CBS overlaps most with a language variant of frontotemporal dementia: progressive nonfluent aphasia (PNFA). The aim of this study was to determine the usefulness of Addenbrooke’s Cognitive Examination-Revised (ACE-R) in the evaluation of CBS and to document similarities and differences between CBS and PNFA. Materials and Methods: Patients with well-defined CBS or PNFA from two tertiary referral centers were selected along with matched controls. Results: Twenty-one patients with CBS, 23 patients with PNFA and 47 age- and education- matched controls were included. Both CBS and PNFA groups showed substantial impairment on the ACE-R (f = 17.3–80.2, p < 0.001) and were significantly impaired in all domains (p < 0.001). The only significant difference between CBS and PNFA was in the visuospatial domain (p < 0.009), being worse in CBS. Using a cutoff of 88/89 out of 100, 90% of CBS and 82.6% of PNFA patients were impaired. At this cutoff of 88/89, ACE-R in CBS had sensitivity and specificity values of 91 and 98%, respectively.

Keywords:
Addenbrookeߣs Cognitive Examination, Addenbrookeߣs Cognitive Examination-Revised, Corticobasal degeneration, Corticobasal syndrome, Progressive aphasia
1.
Rebeiz JJ, Kolodny EH, Richardson EP Jr: Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968;18:20–33.
2.
Graham NL, Bak T, Patterson K, Hodges JR: Language function and dysfunction in corticobasal degeneration. Neurology 2003;61:493–499.
3.
Graham NL, Bak TH, Hodges JR: Corticobasal degeneration as a cognitive disorder. Mov Disord 2003;18:1224–1232.
4.
Mathuranath PS, Xuereb JH, Bak T, Hodges JR: Corticobasal ganglionic degeneration and/or frontotemporal dementia? A report of two overlap cases and review of literature. J Neurol Neurosurg Psychiatry 2000;68:304–312.
5.
Shelley BP, Hodges JR, Kipps CM, Xuereb JH, Bak TH: Is the pathology of corticobasal syndrome predictable in life? Mov Disord 2009;24:1593–1599.
6.
Kertesz A, Martinez-Lage P, Davidson W, Munoz DG: The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology 2000;55:1368–1375.
7.
Kertesz A, McMonagle P: Behavior and cognition in corticobasal degeneration and progressive supranuclear palsy. J Neurol Sci 2010;289:138–143.
8.
Hodges JR, Patterson K: Nonfluent progressive aphasia and semantic dementia: a comparative neuropsychological study. J Int Neuropsychol Soc 1996;2:511–524.
9.
Hodges JR, Patterson K, Oxbury S, Funnell E: Semantic dementia: progressive fluent aphasia with temporal lobe atrophy. Brain 1992;115:1783–1806.
10.
Knibb JA, Xuereb JH, Patterson K, Hodges JR: Clinical and pathological characterization of progressive aphasia. Ann Neurol 2006;59:156–165.
11.
Grimes DA, Lang AE, Bergeron CB: Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 1999;53:1969–1974.
12.
Mathuranath PS, Nestor PJ, Berrios GE, Rakowicz W, Hodges JR: A brief cognitive test battery to differentiate Alzheimer’s disease and frontotemporal dementia. Neurology 2000;55:1613–1620.
13.
Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR: The Addenbrooke’s Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 2006;21:1078–1085.
14.
Jeyapaul P, Kerwick S: Addenbrooke’s Cognitive Examination as a better discriminator of cognitive impairment than the Mini-Mental State Examination in patients with dementia. Int Psychogeriatr 2008;20:642–643.
15.
Larner AJ: Addenbrooke’s Cognitive Examination (ACE) for the diagnosis and differential diagnosis of dementia. Clin Neurol Neurosurg 2007;109:491–494.
16.
Bier JC, Ventura M, Donckels V, Van Eyll E, Claes T, Slama H, Fery P, Vokaer M, Pandolfo M: Is the Addenbrooke’s cognitive examination effective to detect frontotemporal dementia? J Neurol 2004;251:428–431.
17.
Davies RR, Dawson K, Mioshi E, Erzinclioglu S, Hodges JR: Differentiation of semantic dementia and Alzheimer’s disease using the Addenbrooke’s Cognitive Examination (ACE). Int J Geriatr Psychiatry 2008;23:370–375.
18.
Leyton CE, Hornberger M, Mioshi E, Hodges JR: Application of Addenbrooke’s Cognitive Examination to Diagnosis and Monitoring of Progressive Primary Aphasia. Dement Geriatr Cogn Disord 2010;29:504–509.
19.
Bak TH, Crawford LM, Hearn VC, Mathuranath PS, Hodges JR: Subcortical dementia revisited: similarities and differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). Neurocase 2005;11:268–273.
20.
Bak TH, Rogers TT, Crawford LM, Hearn VC, Mathuranath PS, Hodges JR: Cognitive bedside assessment in atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2005;76:420–422.
21.
Bak TH, Hodges JR: Corticobasal degeneration: clinical aspects; in Duyckaerts C, Litvan I (eds): Handbook of Clinical Neurology. Amsterdam, Elsevier, 2008, vol 89, pp 509–521.
22.
McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ: Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick’s Disease. Arch Neurol 2001;58:1803–1809.
23.
Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546–1554.
24.
Murray R, Neumann M, Forman MS, Farmer J, Massimo L, Rice A, Miller BL, Johnson JK, Clark CM, Hurtig HI, Gorno-Tempini ML, Lee VMY, Trojanowski JQ, Grossman M: Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology 2007;68:1274–1283.
25.
Gorno-Tempini ML, Murray RC, Rankin KP, Weiner MW, Miller BL: Clinical, cognitive and anatomical evolution from nonfluent progressive aphasia to corticobasal syndrome: a case report. Neurocase 2004;10:426–436.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.